How much circulating IGF-1 is free?

Only a small fraction. The overwhelming majority is bound, largely in the ternary complex with IGFBP-3 and the acid-labile subunit.

Why does the body sequester IGF-1?

It is a growth factor with receptors on nearly every tissue. The binding system acts as both a reservoir and a brake.

How does LR3 escape it?

Arginine at position 3 removes a charge contributing to binding, and a 13-residue N-terminal extension adds further interference.

IGF-1 LR3

IGF Binding Proteins and the Free Fraction

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

IGF binding proteins sequester the overwhelming majority of circulating IGF-1, largely in a ternary complex with IGFBP-3 and the acid-labile subunit. Bound IGF-1 cannot engage its receptor, so this system controls how much is actually available.

Key facts

Binding protein family: Six IGFBPs
Dominant carrier: IGFBP-3
Third component: Acid-labile subunit (ALS)
Complex: Ternary — IGF-1 + IGFBP-3 + ALS
Effect: Extends half-life, restricts availability
Key review: Baxter, Horm Res 1994 (PMID 7532612)

What the system does

Six IGF binding proteins bind IGF-1 with high affinity. The dominant one in circulation is IGFBP-3, which forms a ternary complex with IGF-1 and the acid-labile subunit. That assembly is too large to leave the vascular compartment easily, which both prolongs IGF-1's presence and restricts where it can act.

Why sequestration is not simply a limitation

IGF-1 is a growth factor with receptors on essentially every tissue and structural similarity to insulin. Uncontrolled availability would be a problem, not a benefit. The binding protein system functions as a reservoir and a brake at once — holding a large circulating pool while keeping the free, active fraction small and regulated.

Research material referenced

IGF-1 LR3 1mg — third-party HPLC tested

View — £37.99

What the acid-labile subunit contributes

ALS is what makes the complex large enough to be retained in circulation. Its importance is demonstrated by what happens when it is missing: Domené and colleagues described acid-labile subunit deficiency in the Journal of Endocrinological Investigation in 2005, a condition in which the ternary complex cannot form and IGF-1 handling is substantially altered.

How LR3 evades it

Two modifications, both aimed at the same target. Arginine at position 3 replaces a glutamate whose negative charge contributes to binding protein interaction. The 13-residue N-terminal extension adds further interference. Together they substantially reduce IGFBP affinity, which raises the free fraction at a given total concentration.

What that means and does not mean

A larger free fraction means more is available to engage receptors at any moment. It does not mean more total activity in any simple sense, because the binding protein system also protects IGF-1 from clearance. Removing the reservoir function while removing the brake changes the whole profile, not just one part of it.

Why this matters for cell culture

Cultured cells secrete their own IGF binding proteins into the medium, which sequester added IGF-1 unpredictably. An analogue that resists them delivers more consistent availability from experiment to experiment — which is the practical reason LR3 exists as a laboratory reagent.

Extended research context

The IGF-1 LR3 deep dive

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications - arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension - exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete - at 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct - and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency - Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has essentially no primary literature under its own name - searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics precisely so that structural modification creates no exemption.

Research applications

▸Cell culture supplementation where secreted IGFBPs confound dosing
▸IGF binding protein interaction and affinity studies
▸Recombinant protein expression and purification methodology
▸Disulfide folding and oxidative refolding research
▸Comparative work on engineered versus native growth factors
▸Anti-doping analytical method development

Handling checklist

✓Expect no PubChem record - proteins are indexed in UniProt (native IGF-1 is P05019)
✓Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
✓Understand that mass spectrometry cannot detect a misfolded disulfide isomer
✓Treat loss of fold as the principal failure mode - it leaves mass unchanged
✓Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
✓Use low-binding consumables; adsorption is significant at microgram quantities
✓Aliquot before freezing - freeze-thaw is worse for a folded protein than a short peptide

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading mecasermin's approval as covering IGF-1 LR3

Fix: Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

✗ Expecting a synthetic-peptide certificate for a recombinant protein

Fix: There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

✗ Treating a clean mass spectrum as proof the protein is intact

Fix: A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

✗ Assuming absence from PubChem is a red flag

Fix: It is expected for a protein of this size - PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is genuinely odd.

✗ Reading the cell-culture rationale as transferable

Fix: Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How much circulating IGF-1 is free?: Only a small fraction. The overwhelming majority is bound, largely in the ternary complex with IGFBP-3 and the acid-labile subunit.
Why does the body sequester IGF-1?: It is a growth factor with receptors on nearly every tissue. The binding system acts as both a reservoir and a brake.
How does LR3 escape it?: Arginine at position 3 removes a charge contributing to binding, and a 13-residue N-terminal extension adds further interference.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum